Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Fewer than 50% of patients with high-risk neuroblastoma survive five years after diagnosis with current treatment protocols. Molecular targeted therapies are expected to improve survival. Although MDM2 has been validated as a promising target in preclinical models, no MDM2 inhibitors have yet entere...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnhold, Viktor, Schmelz, Karin, Proba, Jutta, Winkler, Annika, Wünschel, Jasmin, Toedling, Joern, Deubzer, Hedwig E., Künkele, Annette, Eggert, Angelika, Schulte, Johannes H., Hundsdoerfer, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788641/
https://www.ncbi.nlm.nih.gov/pubmed/29416773
http://dx.doi.org/10.18632/oncotarget.23409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788641/
https://www.ncbi.nlm.nih.gov/pubmed/29416773
http://dx.doi.org/10.18632/oncotarget.23409

Ejemplares similares